A5038173854- Estrogen and related hormone effects
- Immunotherapy and Immune Responses
- Glycosylation and Glycoproteins Research
- Menopause: Health Impacts and Treatments
- Cancer Research and Treatments
- Forensic Toxicology and Drug Analysis
- Cannabis and Cannabinoid Research
- Pharmacogenetics and Drug Metabolism
- Inflammatory mediators and NSAID effects
- Cytokine Signaling Pathways and Interactions
- Lung Cancer Research Studies
- Psychedelics and Drug Studies
- Cancer Treatment and Pharmacology
- Retinoids in leukemia and cellular processes
- Endometrial and Cervical Cancer Treatments
- Monoclonal and Polyclonal Antibodies Research
- Cancer Cells and Metastasis
- Drug Transport and Resistance Mechanisms
- Cancer therapeutics and mechanisms
- Bioactive Compounds and Antitumor Agents
- Neuroscience of respiration and sleep
- Bladder and Urothelial Cancer Treatments
- Phytoestrogen effects and research
- Immune Cell Function and Interaction
- Mass Spectrometry Techniques and Applications
University of California, Davis
2004-2016
Merck (Germany)
2012-2014
Palmetto Hematology Oncology
2012-2013
California State University, Sacramento
2012-2013
University of California Davis Medical Center
2005
Lawrence Livermore National Laboratory
2004
The University of Texas Health Science Center at San Antonio
1992-1998
UC Davis Comprehensive Cancer Center
1998
Texas Biomedical Research Institute
1998
Brooke Army Medical Center
1992-1994
Previous investigators have found no clear relationship between specific blood concentrations of ∆9-tetrahydrocannabinol (∆9-THC) and impairment, thus scientific justification for use legal "per se" ∆9-THC concentration limits. Analyzing from 30 subjects showed that exceeded 5 ng/mL in 16 the following a 12-h period abstinence absence any impairment. In exhaled breath samples collected group 34 at baseline prior to smoking, increasing levels were correlated with (P < 0.0001) suggesting...
Abstract Introduction Ductal carcinoma in situ (DCIS) is a noninvasive premalignant lesion and considered precursor to invasive carcinoma. DCIS accounts for nearly 20% of newly diagnosed breast cancer, but the lack experimentally amenable vivo models hinders development treatment strategies. Here, we demonstrate utility mouse transplantation model chemoprevention studies using selective estrogen receptor modulators (SERMs). This consists set serially transplanted lines genetically engineered...
While current analytical methodologies can readily identify cannabis use, definitively establishing recent use within the impairment window has proven to be far more complex, requiring a new approach. Recent studies have shown no direct relationship between and Δ9-tetra-hydrocannabinol (Δ9-THC) concentrations in blood or saliva, making legal "per se" Δ9-THC limits scientifically unjustified. Current methods that focus on and/or metabolite blood, urine, exhaled breath lead false-positive...
As a result of the legalization U.S. industrial hemp production in late 2018, products containing hemp-derived Δ8-tetrahydrocannabinol (Δ8-THC) are increasing popularity. Little, however, is known regarding Δ8-THC's impairment potential and associated impacts on roadway workplace safety, testing for Δ8-THC not yet common. The present study explored patterns cannabinoid kinetics with recent use Δ8-THC.Hemp-derived concentrate was administered by vaporization ad libitum to three male frequent...
Ospemifene, a new drug indicated for the treatment of vulvovaginal atrophy, has completed phase III clinical trials. A condition affecting millions women worldwide, atrophy long been treated with estrogen therapy. Estrogen carries it risks thromboembolism, endometrial proliferative effects, and breast cancer promotion. In this study, we test effects three dosing levels ospemifene in both prevention MTag.Tg mouse model.The polyomavirus middle-T transgenic model (MTag.Tg), which produces...
Abstract Background L-BLP25 antigen-specific cancer immunotherapeutic agent is currently in phase III clinical trials for non-small cell lung cancer. Using a novel human MUC1 transgenic (hMUC1.Tg) mouse model, we evaluated effects of combined with low-dose cyclophosphamide (CPA) pretreatment on Th1/Th2 cytokine production and antitumor activity. Methods A chemically-induced tumor model was developed hMUC1.Tg C57BL/6 mice by administering 10 weekly 0.75-mg/g doses the chemical carcinogen...
The goals of the present study were to define effects simultaneous cisplatin/tecemotide therapy on tumor development in a human mucin 1 (MUC1) transgenic lung cancer mouse model and examine radiotherapy (RTX) splenocytes, serum cytokines, immune response tecemotide. Two hundred twenty-six MUC1 C57BL/6 mice used five studies designed assess (i) cytokine responses following four weekly 10-μg doses tecemotide; (ii) administration cisplatin (2.5 mg/kg × 2 doses/cycle 4 cycles) tecemotide (2...
Legalization of cannabis for medicinal and/or recreational use is expanding globally. Although being regulated country by country, an accurate recent test with indisputable results correlated impairment has yet to be discovered. In the present study, a new approach determining within window after smoking was developed studying 74 subjects mean age 25 years and average history 9 years. Horizontal gaze nystagmus evaluated along subject self-assessments impairment, blood breath samples were...
In this study, we examine the immunomodulatory effects and antitumor activity of tamoxifen letrozole when combined with human epithelial mucin (hMUC1)-specific vaccine, L-BLP25, in hMUC1-expressing mammary tumor (MMT) mouse model.Dose-finding studies were conducted for both letrozole. Letrozole L-BLP25 combination used 69 MMT female mice assigned to five groups: untreated, cyclophosphamide + placebo, 0.8 mg/kg, Tamoxifen 48 treatment 50 mg/kg group. Mice injected subcutaneously (10 μg)...
We have recently reported immunomodulatory effects for tamoxifen and letrozole on the L-BLP25 (Stimuvax(®))-induced immune response in a MUC1-expressing breast cancer mouse model. While neither nor appeared to interfere with Th1-polarized cytokine induced by L-BLP25, only increased survival advantage of L-BLP25.
Abstract Concurrent and sequential cisplatin-based chemoradiotherapy regimens are standard therapeutic approaches in cancer treatment. Recent clinical data suggest that these different dosing schedules may adversely affect antigen-specific immunotherapy. The goal of the present preclinical study was to explore effects concurrent cisplatin/radiotherapy on immune status a lung mouse model. A total 150 C57BL/6 mice were randomized into six treatment groups: control; 8 Gy thoracic radiotherapy...